Abstract:pulmonary lymphoepithelioma-like carcinoma (PLELC), a rare subtype of non-small cell lung cancer (NSCLC).However, the understanding of the treatment for EBV-infected NSCLC was still elusive.Immunotherapy that targets PD-1/PD-L1 has been utilized as a novel clinical treatment in recent years.Here, we focus on the genomic landscapes of lung cancers with EBV-infection and its correlation with PD-L1.Methods: Patients with both PD-L1 expression detection and genomic information were screened in HapLab database.HaploX 605-gene panel sequencing, covering 1.31 MB genome, was performed to analyze the genomic data of patients.PD-L1 expression was detected by immunochemistry.Bioinformatic analysis of genomic mutations and the correlation with the expression of PD-L1 were studied.Results: We analyzed the genomic profiles of 23 EBV-infected NSCLC patients.11 cases of lung squamous-cell carcinoma (LUSC), 4 cases of lung adenocarcinoma (LUAD), 5 cases of lung pulmonary lymphoepithelioma-like carcinoma (PLELC), and 3 unidentified cases were included in this study.Collectively, 93 genome mutations of 67 genes were detected in 23 EBV-infection cases.Top 3 frequently mutated genes were TP53 (27%), CSMD3 (18%) and KMT2D (18%).The EBV-infected patients exhibited a low level of tumor mutation burden (TMB).The median TMB was 1.53 Muts/MB (ranging from 0 to 14.5 Muts/MB).Only 3 of 23 patients (13.0%) harbored the canonical driver mutations in NSCLC.Interestingly, 10/23 patients (43.5%) showed high expression of PD-L1, while 13/23 patients (56.5%) showed low expression.We also assessed the expression of PD-L1 in lung cancers with no EBV-infection (867 cases).Only 118/867 (13.6%) patients without EBV-infection presented high PD-L1 expression, while 749/867 (86.4%) presented low PD-L1 expression.Conclusion: EBV-infection can occur in different kinds of NSCLC, including LUSC, LUAD, and PLELC.TMB and driver mutations of EBV-infected NSCLC were not frequently observed as normal lung cancers, implying a different mechanism leading to EBVinfected lung cancers.Interestingly, EBV-infected NSCLC tended to have a high correlation with the expression of PD-L1.This may give a hint on the application of checkpoint blockade immunotherapy on EBV-infected NSCLC.

Combined Flow-Fluorescence in situ hybridization to HHV-8 and EBV reveals the viral heterogeneity of primary effusion lymphoma

Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV

Complete absence of KSHV/HHV-8 in posttransplant lymphoproliferative disorders: an immunohistochemical and molecular study of 52 cases.

[Application of Flow Cytometry Combined Fluorescence in Situ Hybridization to Indentify the Lymphocyte Subtypies with Epstein-Barr Virus Infection]

Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH

Path-35. Integrated Genomic Analyses Of Immunodeficiency-Associated Epstein-Barr Virus- (Ebv) Positive Primary Cns Lymphomas

Extracavitary/solid Variant of Primary Effusion Lymphoma Presenting As a Gastric Mass

Partial absence of PD-1 expression by tumor-infiltrating EBV-specific CD8+ T cells in EBV-driven lymphoepithelioma-like carcinoma

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study

Identification of Viral SIM-SUMO2-interaction Inhibitors for Treating Primary Effusion Lymphoma.

Distinct Molecular Landscape of Epstein–Barr Virus Associated Pulmonary Lymphoepithelioma-Like Carcinoma Revealed by Genomic Sequencing

[Lymphocytic Clonal Expansion in Adult Patients with Epstein-Barr Virus-Associated Lymphoproliferative Disease].

Differentiating Between Epstein-Barr Virus–positive Lymphoid Neoplasm Relapse and Post-transplant Lymphoproliferative Disorder After Sex-mismatched Hematopoietic Stem Cell Transplantation

Molecular Features of HHV8 Monoclonal Microlymphoma Associated with Kaposi Sarcoma and Multicentric Castleman Disease in an HIV-Negative Patient

Clonal heterogeneity of polymorphic B-cell lymphoproliferative disease, EBV-positive, iatrogenic/immune senescence: implications on pathogenesis and treatment

P35.22 WITHDRAWN

Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation within the Classic Hodgkin Lymphoma Tumor Microenvironment

A Rare Case of Systemic Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis in an Immunocompetent Young Man: Potential Diagnostic Pitfall and Therapeutic Challenge

Prognostic Role of the Expression of Latent-Membrane Protein 1 of Epstein-Barr Virus in Classical Hodgkin Lymphoma

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma